secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-280125
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q3 net loss $61.5M ($1.16/share); cash $72M; Phase 3 trials on track
--------------------------------------------------------------------------------

- Net loss of $61.5M ($1.16/sh) vs $43.9M ($0.84/sh) in Q3 2024; R&D expenses rose to $50.5M from $31.9M on higher clinical and manufacturing activity.
- Cash and equivalents $72.0M as of Sept 30, 2025, down from prior quarter given ongoing Phase 3 spend.
- Phase 1b APEX (KSI-101) showed ≥90% of patients in top doses achieved absence of retinal fluid; Phase 3 PEAK/PINNACLE enrolling faster than expected.
- Phase 3 DAYBREAK (tarcocimab/KSI-501) in wet AMD completed enrollment of ~690 patients; topline data expected 3Q 2026.
- Upcoming catalysts: GLOW2 topline 1Q 2026; KSI 101 Phase 3 topline 4Q 2026/1Q 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000119312525280125/0001193125-25-280125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000119312525280125/kod-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-280125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer